As the array of ETF product offerings has expanded in recent years, the biotech space has seen significant activity. Currently, there are five biotech ETFs that have accumulated nearly $3.5 billion in aggregate assets. Each of these funds focuses on stocks in the biotechnology industry, and in many cases there is significant overlap between the top holdings. But as the relative performance of these funds so far this year has shown, the biotech ETFs available to U.S. investors are far from identical. Each of the biotech ETFs is up at least 6% so far in 2010, making this sector one of the best performers of the year. But the top-performing biotech ETF is up nearly 25% on the year, a significant return gap between funds that seem, at least on the surface, to be relatively comparable. The significant performance gaps between these funds can be traced to the allocations made to a handful of biotech companies that have seen shares surge this year. Weightings given to some of the year’s top-performing stocks are all over the board for the various biotech ETFs; the companies highlighted below are among the top components of some funds and are excluded altogether from others.
A quick look at the weightings given to each of these companies by the four major biotech ETFs sheds some light on the big gaps in year-to-date performance. These stocks are the four largest components of FBT, accounting for nearly 30% of assets. The biotech ETFs from PowerShares, State Street, and iShares give significantly less weight to these stocks; they account for only about 9% of PBE, 5% of XBI, and less than 2% of IBB.
The moral of the story? Funds may look similar on the surface, but the composition and nature of the underlying index can have a major impact on bottom line returns (see our index database for a unique way to screen ETFs by their related benchmark). Sign up for our free ETF newsletter for more head-to-head comparisons of sector ETFs. Disclosure: No positions at time of writing.
updated Mar 08, 2010
Sign up to get our newsletter with money saving tips, travel hacks and more - no spam.
discounts & deals from all banks in one app?
At GET.com we compare credit cards and rate them objectively based on the credit card's features, interest rates and fees.
Cards are rated by our team based primarily on the basis of value for money to the cardholder. The GET.com team rates each card based on its annual fee, rewards, benefits, bonus, introductory APR, ongoing APR, flexibility (in how its benefits can be used and how rewards are earned and redeemed), and other card features.